Organisation
Hepatology
Division
The labo of Hepatology studies pathophysiology and treatment of liver and pancreas diseases and metabolism.
Current researchers
1 - 10 of 15 results
- Schalk Van der Merwe (Responsible)
- Isabelle Adant (Member)
- David Cassiman (Member)
- Rita Furtado Feio De Azevedo (Member)
- Hannelie Korf (Member)
- Wim Laleman (Member)
- Louis Libbrecht (Member)
- Frederik Nevens (Member)
- Lukas Van Melkebeke (Member)
- Marc Van de Casteele (Member)
Projects
1 - 10 of 51
- Unravelling aberrant host-microbiota interactions underlying intestinal epithelial barrier failure in cirrhosisFrom7 Feb 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Harnessing single-cell and spatial transcriptomics to uncover novel insights into the pathological events that trigger the progression of acute-on-chronic liver failureFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Deciphering the molecular mechanism that account for intestinal barrier dysfunction in cirrhosisFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Harnessing Single-Cell and Spatial Transcriptomics to Uncover Novel Insights into Intestinal Barrier Breach in CirrhosisFrom1 Oct 2023 → TodayFunding: Fund Recuperation Fiscal Exemption, BOF - projects
- Exploring the molecular mechanisms underlying bacterial translocation in cirrhosisFrom29 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Harnessing single-cell and spatial transcriptomics to uncover novel insights into the pathological events that trigger the progression of acute-on-chronic liver failureFrom1 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation and implementation of a prognostic biomarker of early graft failure after liver transplantation (GlycoTransplantTest)From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Model-informed precision dosing of tacrolimus in solid organ transplant recipientsFrom27 Jul 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Design of robotic catheter and endoscopic systems for cancer treatmentFrom16 Feb 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Stratifying risk and individualizing care for patients with clinically significant portal hypertension (CSPH)From7 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 1330
- Increasing the tolerance for warm ischemia of livers in transplantation by the leuven drug protocol(2011)
Authors: Katrien Vekemans, Diethard Monbaliu, Erika Balligand, Veerle Heedfeld, Jacques Pirenne, Jos van Pelt
Pages: S211 - S211 - Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals(2016)
Authors: Frederik Nevens, Ingele Casteels
Pages: Doc05 - Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study(2016)
Authors: Palak J Trivedi, Willem J Lammers, Henk R van Buuren, Albert Parés, Annarosa Floreani, Harry L A Janssen, Pietro Invernizzi, Pier Maria Battezzati, Cyriel Y Ponsioen, Christophe Corpechot, et al.
Pages: 321 - 9 - Correction to 'Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF' [J Hepatol 2020 (72) 688-701].(2020)
Authors: Richard Moreau, Joan Clària, Ferran Aguilar, François Fenaille, Juan José Lozano, Christophe Junot, Benoit Colsch, Paolo Caraceni, Jonel Trebicka, Marco Pavesi, et al.
Pages: 1218 - 1220 - Role of vasoactive substances and cellular effectors in the pathophysiology of cirrhotic portal hypertension: the past, the present and the future - Georges Brohee lecture(2009)
Authors: Wim Laleman
Pages: 9 - 16 - Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test(2019)
Authors: Carla Fiorella Murillo Perez, Aliya Gulamhusein, Marco Carbone, Palak Trivedi, Adriaan Van der Meer, Christophe Corpechot, Pier Maria Battezzati, Willem J Lammers, Annarosa Floreani, Albert Pares, et al.
Pages: E404 - E404 - SECOND-LINE THERAPY IS INDICATED IN URSODEOXYCHOLIC ACID-TREATED PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND HIGH ALKALINE PHOSPHATASE DESPITE A COMPLETE GLOBE-SCORE RESPONSE(2019)
Authors: Rozanne de Veer, Maren H Harms, Christophe Corpechot, Willem J Lammers, Douglas Thorburn, Pietro Invernizzi, Harry LA Janssen, Pier Maria Battezzati, Frederik Nevens, Keith D Lindor, et al.
Pages: 783A - 785A - ADDITIVE BENEFICIAL EFFECTS OF FIBRATES COMBINED WITH OBETICHOLIC ACID IN THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND INADEQUATE RESPONSE TO SECOND-LINE THERAPY(2019)
Authors: Pierre-Antoine Soret, Laurent Lam, Fabrice Carrat, Lena Smets, Vincent Leroy, Thomas Berg, Marco Carbone, Pietro Invernizzi, Palak Trivedi, Christina Weiler-Normann, et al.
Pages: 1491A - 1492A - Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 years(2017)
Authors: CFM Perez, WJ Lammers, JC Goet, HL Janssen, HR van Buuren, A Mason, C Corpechot, P Invernizzi, MJ Mayo, PM Battezzati, et al.
Pages: S358 - S358 - MIR141 AND MIR200C REGULATE PROGENITOR CELL FEATURES IN HEPATOCELLULAR CARCINOMAS(2011)
Authors: Olivier Govaere, Joost Berkers, L van Kempen, Kathleen Van den Eynde, M Komuta, B Spee, R Aerts, Baki Topal, Frederik Nevens, Evelyne Lerut, et al.
Pages: S91 - S92